Cargando…
SARS-CoV-2–neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683250/ https://www.ncbi.nlm.nih.gov/pubmed/34911078 http://dx.doi.org/10.1182/bloodadvances.2021006655 |
| _version_ | 1784617373792206848 |
|---|---|
| author | Malin, Jakob J. Di Cristanziano, Veronica Horn, Carola Pracht, Elisabeth Garcia Borrega, Jorge Heger, Eva Knops, Elena Kaiser, Rolf Böll, Boris Lehmann, Clara Jung, Norma Borchmann, Peter Fätkenheuer, Gerd Klein, Florian Hallek, Michael Rybniker, Jan |
| author_facet | Malin, Jakob J. Di Cristanziano, Veronica Horn, Carola Pracht, Elisabeth Garcia Borrega, Jorge Heger, Eva Knops, Elena Kaiser, Rolf Böll, Boris Lehmann, Clara Jung, Norma Borchmann, Peter Fätkenheuer, Gerd Klein, Florian Hallek, Michael Rybniker, Jan |
| author_sort | Malin, Jakob J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8683250 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86832502021-12-20 SARS-CoV-2–neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma Malin, Jakob J. Di Cristanziano, Veronica Horn, Carola Pracht, Elisabeth Garcia Borrega, Jorge Heger, Eva Knops, Elena Kaiser, Rolf Böll, Boris Lehmann, Clara Jung, Norma Borchmann, Peter Fätkenheuer, Gerd Klein, Florian Hallek, Michael Rybniker, Jan Blood Adv Research Letter American Society of Hematology 2022-03-07 /pmc/articles/PMC8683250/ /pubmed/34911078 http://dx.doi.org/10.1182/bloodadvances.2021006655 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://www.ncbi.nlm.nih.gov/pmc/pmcdoc/tagging-guidelines/article/tags.html#el-licenseThis article is made available via the PMC Open Access Subset for unrestricted reuse and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. |
| spellingShingle | Research Letter Malin, Jakob J. Di Cristanziano, Veronica Horn, Carola Pracht, Elisabeth Garcia Borrega, Jorge Heger, Eva Knops, Elena Kaiser, Rolf Böll, Boris Lehmann, Clara Jung, Norma Borchmann, Peter Fätkenheuer, Gerd Klein, Florian Hallek, Michael Rybniker, Jan SARS-CoV-2–neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma |
| title | SARS-CoV-2–neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma |
| title_full | SARS-CoV-2–neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma |
| title_fullStr | SARS-CoV-2–neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma |
| title_full_unstemmed | SARS-CoV-2–neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma |
| title_short | SARS-CoV-2–neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma |
| title_sort | sars-cov-2–neutralizing antibody treatment in patients with covid-19 and immunodeficiency due to b-cell non-hodgkin lymphoma |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683250/ https://www.ncbi.nlm.nih.gov/pubmed/34911078 http://dx.doi.org/10.1182/bloodadvances.2021006655 |
| work_keys_str_mv | AT malinjakobj sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma AT dicristanzianoveronica sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma AT horncarola sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma AT prachtelisabeth sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma AT garciaborregajorge sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma AT hegereva sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma AT knopselena sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma AT kaiserrolf sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma AT bollboris sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma AT lehmannclara sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma AT jungnorma sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma AT borchmannpeter sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma AT fatkenheuergerd sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma AT kleinflorian sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma AT hallekmichael sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma AT rybnikerjan sarscov2neutralizingantibodytreatmentinpatientswithcovid19andimmunodeficiencyduetobcellnonhodgkinlymphoma |